Open Access

Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis

  • Jérémie Sellam1, 10Email author,
  • Elodie Rivière2,
  • Alice Courties1,
  • Paul-Olivier Rouzaire3,
  • Barbara Tolusso4,
  • Edward M. Vital5,
  • Paul Emery5,
  • Gianfranco Ferraccioli4,
  • Martin Soubrier6,
  • Bineta Ly2,
  • Houria Hendel Chavez7,
  • Yassine Taoufik7,
  • Maxime Dougados8 and
  • Xavier Mariette2, 9Email author
Contributed equally
Arthritis Research & Therapy201719:11

https://doi.org/10.1186/s13075-017-1221-4

Received: 6 January 2017

Accepted: 6 January 2017

Published: 23 January 2017

The original article was published in Arthritis Research & Therapy 2016 18:294

Erratum

Unfortunately, after publication of this article [1], it was noticed that the name of Gianfranco Ferraccioli was incorrectly spelled as Gianfranco Ferraciolli. The corrected author list can be seen above and the original article has been updated to correct this error.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Université Paris 06, AP-HP St-Antoine hospital, Rheumatology Department, INSERM UMRS_938
(2)
Université Paris-Sud, AP-HP Hôpitaux Universitaires Paris-Sud, Rheumatology Department, Center for Immunology of Viral Infections and Autoimmune Diseases INSERM U1184
(3)
Biological Immunology Department, ERTICa Research Group, Clermont-Ferrand University Hospital
(4)
Rheumatology Department, Catholic University of the Sacred Heart
(5)
NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds
(6)
Rheumatology Department, Clermont-Ferrand University Hospital
(7)
AP-HP Bicêtre Hospital, Biological Immunology Department, INSERM U1184
(8)
Department of Rheumatology - Hôpital Cochin, Paris Descartes University, Assistance Publique - Hôpitaux de Paris, INSERM (U1153), Clinical Epidemiology and Biostatistics
(9)
Service de Rhumatologie, Hôpital de Bicêtre
(10)
Service de Rhumatologie, Hôpital Saint-Antoine

Reference

  1. Sellam J, Rivière E, Courties A, Rouzaire PO, Tolusso B, Vital EM, Emery P, Ferraccioli G, Soubrier M, Ly B, Hendel Chavez H, Taoufik Y, Dougados M, Mariette X. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res Ther. 2016;18:294. http://doi.org/10.1186/s13075-016-1190-z.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement